Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 11 de 11
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
J Perianesth Nurs ; 2024 Jul 17.
Article de Anglais | MEDLINE | ID: mdl-39023476

RÉSUMÉ

PURPOSE: The use of perineural dexamethasone as an adjuvant drug to peripheral nerve block for postoperative pain is controversial. This systematic review aimed to determine the effectiveness of adding dexamethasone to lidocaine in upper limb nerve blocks. DESIGN: Systematic review. METHODS: This review used a comprehensive search strategy to retrieve relevant published randomized trial articles that fulfilled the inclusion and exclusion criteria, without time limits, (until December 2023) that assessed the effects of a combination of dexamethasone to lidocaine in upper limb nerve blocks. The databases used for the electronic literature search included PubMed, Embase, and Clinical Trials.gov, dbGaP, Cochrane library, and Google Scholar. There was no language, gender, or age limitation. This systematic review is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement. FINDINGS: Of 3,926 articles identified by the initial search, 8 studies that met our inclusion criteria. All articles were original research studies. All eight articles were clinical trials. The sample size in the selected studies ranged from 30 to 90 people. Studies demonstrated that combining dexamethasone with lidocaine significantly improved the quality of peripheral nerve blocks, increased the analgesia period, and decreased analgesic consumption. CONCLUSIONS: This review supported that the combination of dexamethasone (dose of 4 to 10 mg) and lidocaine (concentration of 1.5% to 2%) for upper limb block was more effective and beneficial without any side effects. However, further clinical trials in this regard with more data, various regions, and larger sample sizes to support our hypothesis are recommended.

2.
J Reprod Immunol ; 165: 104283, 2024 Jun 25.
Article de Anglais | MEDLINE | ID: mdl-38991487

RÉSUMÉ

Genital tract infections can cause a variety of harmful health outcomes, including endometritis, bacterial vaginosis, and pelvic inflammatory disease, in addition to infertility. Anaerobic bacteria, such as Gardnerella vaginalis, Megasphaera spp., and Atopobium vaginae, are more commonly identified in cases of bacterial vaginosis than lactobacilli. It is unknown how the microorganisms that cause pelvic inflammatory diseases and endometritis enter the uterus. Both prospective and retrospective research have connected pelvic inflammatory disorders, chronic endometritis, and bacterial vaginosis to infertility. Similar to bacterial vaginosis, endometritis-related infertility is probably caused by a variety of factors, such as inflammation, immune system recognition of sperm antigens, bacterial toxins, and a higher risk of STDs. Preconception care for symptomatic women may include diagnosing and treating pelvic inflammatory disease, chronic endometritis, and bacterial vaginosis before conception to optimize the results of both natural and assisted reproduction.

4.
Article de Anglais | MEDLINE | ID: mdl-39073420

RÉSUMÉ

This review paper provides an in-depth analysis of Perovskite quantum dots (PQDs), a class of nanomaterials with unique optical and electronic properties that hold immense potential for various technological applications. The paper delves into the structural characteristics, synthesis methods, and characterization techniques of PQDs, highlighting their distinct advantages over other Quantum Dots (QDs). Various applications of PQDs in fields such as solar cells, LEDs, bioimaging, photocatalysis, and sensors are discussed, showcasing their versatility and promising capabilities. The ongoing advancements in PQD research and development point towards a bright future for these nanostructures in revolutionizing diverse industries and technologies.

5.
Med Oncol ; 41(8): 201, 2024 Jul 13.
Article de Anglais | MEDLINE | ID: mdl-39001987

RÉSUMÉ

Pancreatic cancer remains a significant health issue with limited treatment options. The tumor stroma, a complex environment made up of different cells and proteins, plays a crucial role in tumor growth and chemoresistance. Targeting tumor stroma, consisting of diverse non-tumor cells such as fibroblasts, extracellular matrix (ECM), immune cells, and also pre-vascular cells is encouraging for remodeling solid cancers, such as pancreatic cancer. Remodeling the stroma of pancreas tumors can be suggested as a strategy for reducing resistance to chemo/immunotherapy. Several studies have shown that phytochemicals from plants can affect the tumor environment and have anti-cancer properties. By targeting key pathways involved in stromal activation, phytochemicals may disrupt communication between the tumor and stroma and make tumor cells more sensitive to different treatments. Additionally, phytochemicals have immunomodulatory and anti-angiogenic properties, all of which contribute to their potential in treating pancreatic cancer. This review will provide a detailed look at how phytochemicals impact the tumor stroma and their effects on pancreatic tumor growth, spread, and response to treatment. It will also explore the potential of combining phytochemicals with other treatment options like chemotherapy, immunotherapy, and radiation.


Sujet(s)
Tumeurs du pancréas , Composés phytochimiques , Microenvironnement tumoral , Humains , Tumeurs du pancréas/traitement médicamenteux , Tumeurs du pancréas/anatomopathologie , Microenvironnement tumoral/effets des médicaments et des substances chimiques , Composés phytochimiques/pharmacologie , Composés phytochimiques/usage thérapeutique , Animaux , Antinéoplasiques d'origine végétale/pharmacologie , Antinéoplasiques d'origine végétale/usage thérapeutique , Nanoparticules
6.
AAPS PharmSciTech ; 25(6): 140, 2024 Jun 18.
Article de Anglais | MEDLINE | ID: mdl-38890191

RÉSUMÉ

Nanotechnology has significantly transformed cancer treatment by introducing innovative methods for delivering drugs effectively. This literature review provided an in-depth analysis of the role of nanocarriers in cancer therapy, with a particular focus on the critical concept of the 'stealth effect.' The stealth effect refers to the ability of nanocarriers to evade the immune system and overcome physiological barriers. The review investigated the design and composition of various nanocarriers, such as liposomes, micelles, and inorganic nanoparticles, highlighting the importance of surface modifications and functionalization. The complex interaction between the immune system, opsonization, phagocytosis, and the protein corona was examined to understand the stealth effect. The review carefully evaluated strategies to enhance the stealth effect, including surface coating with polymers, biomimetic camouflage, and targeting ligands. The in vivo behavior of stealth nanocarriers and their impact on pharmacokinetics, biodistribution, and toxicity were also systematically examined. Additionally, the review presented clinical applications, case studies of approved nanocarrier-based cancer therapies, and emerging formulations in clinical trials. Future directions and obstacles in the field, such as advancements in nanocarrier engineering, personalized nanomedicine, regulatory considerations, and ethical implications, were discussed in detail. The review concluded by summarizing key findings and emphasizing the transformative potential of stealth nanocarriers in revolutionizing cancer therapy. This review enhanced the comprehension of nanocarrier-based cancer therapies and their potential impact by providing insights into advanced studies, clinical applications, and regulatory considerations.


Sujet(s)
Antinéoplasiques , Vecteurs de médicaments , Nanoparticules , Tumeurs , Humains , Tumeurs/traitement médicamenteux , Vecteurs de médicaments/composition chimique , Nanoparticules/composition chimique , Antinéoplasiques/administration et posologie , Antinéoplasiques/pharmacocinétique , Antinéoplasiques/composition chimique , Animaux , Systèmes de délivrance de médicaments/méthodes , Nanomédecine/méthodes , Liposomes , Micelles , Distribution tissulaire
7.
J Reprod Immunol ; 164: 104274, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38865894

RÉSUMÉ

Numerous recent studies have examined the impact epigenetics-including DNA methylation-has on spermatogenesis and male infertility. Differential methylation of several genes has been linked to compromised spermatogenesis and/or reproductive failure. Specifically, male infertility has been frequently associated with DNA methylation abnormalities of MEST and H19 inside imprinted genes and MTHFR within non-imprinted genes. Microbial infections mainly result in male infertility because of the immune response triggered by the bacteria' accumulation of immune cells, proinflammatory cytokines, and chemokines. Thus, bacterially produced epigenetic dysregulations may impact host cell function, supporting host defense or enabling pathogen persistence. So, it is possible to think of pathogenic bacteria as potential epimutagens that can alter the epigenome. It has been demonstrated that dysregulated levels of LncRNA correlate with motility and sperm count in ejaculated spermatozoa from infertile males. Therefore, a thorough understanding of the relationship between decreased reproductive capacity and sperm DNA methylation status should aid in creating new diagnostic instruments for this condition. To fully understand the mechanisms influencing sperm methylation and how they relate to male infertility, more research is required.


Sujet(s)
Méthylation de l'ADN , Épigenèse génétique , Infertilité masculine , Spermatogenèse , Spermatozoïdes , Mâle , Humains , Infertilité masculine/immunologie , Infertilité masculine/génétique , Infertilité masculine/microbiologie , Épigenèse génétique/immunologie , Méthylation de l'ADN/immunologie , Spermatozoïdes/immunologie , Spermatogenèse/génétique , Spermatogenèse/immunologie , Animaux , ARN long non codant/génétique , ARN long non codant/immunologie , Infections bactériennes/immunologie , Infections bactériennes/génétique , Methylenetetrahydrofolate reductase (NADPH2)/génétique
8.
Cell Biochem Funct ; 42(4): e4029, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38773914

RÉSUMÉ

Mesenchymal stem cell-derived exosomes (MSC-Exos) are emerging as remarkable agents in the field of immunomodulation with vast potential for diagnosing and treating various diseases, including cancer and autoimmune disorders. These tiny vesicles are laden with a diverse cargo encompassing proteins, nucleic acids, lipids, and bioactive molecules, offering a wealth of biomarkers and therapeutic options. MSC-Exos exhibit their immunomodulatory prowess by skillfully regulating pattern-recognition receptors (PRRs). They conduct a symphony of immunological responses, modulating B-cell activities, polarizing macrophages toward anti-inflammatory phenotypes, and fine-tuning T-cell activity. These interactions have profound implications for precision medicine, cancer immunotherapy, autoimmune disease management, biomarker discovery, and regulatory approvals. MSC-Exos promises to usher in a new era of tailored therapies, personalized diagnostics, and more effective treatments for various medical conditions. As research advances, their transformative potential in healthcare becomes increasingly evident.


Sujet(s)
Exosomes , Cellules souches mésenchymateuses , Récepteurs de reconnaissance de motifs moléculaires , Humains , Exosomes/métabolisme , Cellules souches mésenchymateuses/métabolisme , Cellules souches mésenchymateuses/immunologie , Cellules souches mésenchymateuses/cytologie , Récepteurs de reconnaissance de motifs moléculaires/métabolisme , Animaux , Immunomodulation
9.
Mol Biol Rep ; 51(1): 629, 2024 May 08.
Article de Anglais | MEDLINE | ID: mdl-38717637

RÉSUMÉ

It has been rediscovered in the last fifteen years that B-cells play an active role in autoimmune etiology rather than just being spectators. The clinical success of B-cell depletion therapies (BCDTs) has contributed to this. BCDTs, including those that target CD20, CD19, and BAFF, were first developed to eradicate malignant B-cells. These days, they treat autoimmune conditions like multiple sclerosis and systemic lupus erythematosus. Particular surprises have resulted from the use of BCDTs in autoimmune diseases. For example, even in cases where BCDT is used to treat the condition, its effects on antibody-secreting plasma cells and antibody levels are restricted, even though these cells are regarded to play a detrimental pathogenic role in autoimmune diseases. In this Review, we provide an update on our knowledge of the biology of B-cells, examine the outcomes of clinical studies employing BCDT for autoimmune reasons, talk about potential explanations for the drug's mode of action, and make predictions about future approaches to targeting B-cells other than depletion.


Sujet(s)
Maladies auto-immunes , Lymphocytes B , Déplétion lymphocytaire , Animaux , Humains , Antigènes CD19/immunologie , Antigènes CD20/immunologie , Maladies auto-immunes/immunologie , Maladies auto-immunes/thérapie , Facteur d'activation des lymphocytes B/immunologie , Lymphocytes B/immunologie , Lupus érythémateux disséminé/immunologie , Lupus érythémateux disséminé/thérapie , Déplétion lymphocytaire/méthodes , Sclérose en plaques/immunologie , Sclérose en plaques/thérapie
10.
Pathol Res Pract ; 256: 155261, 2024 Apr.
Article de Anglais | MEDLINE | ID: mdl-38518733

RÉSUMÉ

Through their ability to modify the tumor microenvironment and cancer cells, macrophages play a crucial role in the promotion of tumorigenesis, development of tumors and metastasis, and chemotherapy resistance. A growing body of research has indicated that exosomes may be essential for coordinating the communication between cancer cells and macrophages. One type of extracellular vehicle called an exosome is utilized for delivering a variety of molecules, such as proteins, lipids, and nucleic acids, to specific cells in order to produce pleiotropic effects. Exosomes derived from macrophages exhibit heterogeneity across various cancer types and function paradoxically, suppressing tumor growth while stimulating it, primarily through post-transcriptional control and protein phosphorylation regulation in the receiving cells. Exosomes released by various macrophage phenotypes offer a variety of therapeutic alternatives in the interim. We outlined the most recent developments in this article, including our understanding of the roles that mechanisms and macrophage-derived exosomal biogenesis play in mediating the progression of cancer and their possible therapeutic uses.


Sujet(s)
Exosomes , microARN , Tumeurs , Humains , microARN/génétique , Exosomes/métabolisme , Tumeurs/anatomopathologie , Macrophages/anatomopathologie , Prolifération cellulaire , Microenvironnement tumoral/génétique
11.
Pathol Res Pract ; 256: 155266, 2024 Apr.
Article de Anglais | MEDLINE | ID: mdl-38554489

RÉSUMÉ

Hepatic tumors present a formidable challenge in cancer therapeutics, necessitating the exploration of novel treatment strategies. In recent years, targeting the immune system has attracted interest to augment existing therapeutic efficacy. The immune system in hepatic tumors includes numerous cells with diverse actions. CD8+ T lymphocytes, T helper 1 (Th1) CD4+ T lymphocytes, alternative M1 macrophages, and natural killer (NK) cells provide the antitumor immunity. However, Foxp3+ regulatory CD4+ T cells (Tregs), M2-like tumor-associated macrophages (TAMs), and myeloid-derived suppressor cells (MDSCs) are the key immune inhibitor cells. Tumor stroma can also affect these interactions. Targeting these cells and their secreted molecules is intriguing for eliminating malignant cells. The current review provides a synopsis of the immune system components involved in hepatic tumor expansion and highlights the molecular and cellular pathways that can be targeted for therapeutic intervention. It also overviews the diverse range of drugs, natural products, immunotherapy drugs, and nanoparticles that have been investigated to manipulate immune responses and bolster antitumor immunity. The review also addresses the potential advantages and challenges associated with these approaches.


Sujet(s)
Produits biologiques , Tumeurs du foie , Nanoparticules , Tumeurs , Humains , Produits biologiques/usage thérapeutique , Produits biologiques/métabolisme , Tumeurs/anatomopathologie , Immunothérapie , Macrophages/anatomopathologie , Tumeurs du foie/anatomopathologie , Nanoparticules/usage thérapeutique , Microenvironnement tumoral
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE